{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015242","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.136509+00:00","generated_at":"2026-05-19T05:54:06.418743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K","bullets":["Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.","Net loss improved to $580K from $857K in same quarter last year.","Adjusted net loss (excl. share-based comp) was $547K vs $825K YoY.","EPS remained ($0.01) for both quarters; nine-month EPS ($0.02) vs ($0.03) last year.","CEO reports SDC dairy membrane solution now commercial at full-scale dairy plants."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015242","json":"https://secwatch.observer/filing/0001641172-25-015242.json","markdown":"https://secwatch.observer/filing/0001641172-25-015242.md","text":"https://secwatch.observer/filing/0001641172-25-015242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000164117225015242/0001641172-25-015242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000164117225015242/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:54:06.418743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}